Fortive Corp. 8-K Summary: February 21, 2019
Business Context and Reporting Period
This Form 8-K, filed on February 21, 2019, reports material definitive agreements entered into by Fortive Corporation (Fortive) on February 21 and 22, 2019. The primary event is the issuance of convertible senior notes to fund a pending acquisition.
Key Financial Metrics and Capital Structure
- Debt Issuance: Fortive issued $1.4375 billion in aggregate principal amount of 0.875% Convertible Senior Notes due 2022. This includes $187.5 million from the full exercise of an over-allotment option.
- Interest Rate: 0.875% per year, payable semiannually beginning August 15, 2019.
- Maturity: February 15, 2022.
- Conversion Terms: Initial conversion rate of 9.3777 shares per $1,000 principal amount (approx. $106.64 per share), representing a 32.5% premium to the $80.48 closing price on February 19, 2019.
- Guarantees: The Notes are fully and unconditionally guaranteed by four wholly-owned domestic subsidiaries.
- Use of Proceeds: Net proceeds are intended to fund a portion of the cash consideration for the acquisition of the Advanced Sterilization Products (ASP) business from Ethicon, Inc. (Johnson & Johnson).
Material Changes and Agreements
- Convertible Notes: The Notes are senior unsecured obligations, ranking equally with existing unsecured debt but effectively junior to secured indebtedness. They are structurally subordinated to obligations of non-guarantor subsidiaries.
- Redemption and Repurchase: The Notes are not redeemable prior to maturity. However, holders may require Fortive to repurchase the Notes at 100% of principal plus accrued interest if a "fundamental change" occurs.
- Credit Facility Amendments: Fortive amended its Term Loan and Revolving Credit Facilities to exclude the new Guarantees from limitations on subsidiary indebtedness.
Outlook, Risks, and Contingencies
- Acquisition Contingency: If the ASP acquisition is not completed, proceeds will be used for working capital, general corporate purposes, potential future acquisitions, capital expenditures, refinancing, share repurchases, or dividends.
- Settlement Method: Fortive intends to settle conversions in cash up to the principal amount, with any excess conversion value settled in shares.
- Financial Statements: This filing does not contain audited financial statements, revenue, profit, or cash flow data for a specific reporting period; it focuses solely on the capital transaction.
Key Facts for Investor Verification
- Verify the status and expected closing date of the Advanced Sterilization Products (ASP) acquisition from Johnson & Johnson.
- Confirm the impact of the $1.4375 billion debt issuance on Fortive's leverage ratios and liquidity position.
- Monitor the stock price relative to the $106.64 conversion price to assess the likelihood of conversion versus cash settlement.
- Review the specific terms of the "fundamental change" repurchase option in the Indenture (Exhibit 4.1).